BRAF and melanoma: Even in tumor models different from melanoma, such as BRAF- wt/RAS-mutant (mut) lung and pancreatic cancers, we confirmed paradoxical MAPK reactivation upon pharmacological BRAF kinase inhibition; however, simultaneous treatment with MEK inhibitors switched MAPK off again and induced a synergistic reduction of cell growth both in vitro and in vivo [30].